A new type of CFTR corrector has been discovered, called tricyclic pyrrolo-quinolines, which has proven effective in primary airway epithelial cells from CF patients with the F508del mutation through a functional test [151]. The gene discussed is CFTR; the disease is cystic fibrosis.